Developing Digital Biomarkers Post Covid-19

Developing Digital Biomarkers Post COVID-19

The 3rd Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche was the virtual place to be in June, bringing together 250+ global thought leaders and experts. They shared insights on developing and improving the way pharma clinical trials utilize mobile-enabled, wearables, and IoT capabilities to augment existing biomarker strategies, improve patient experience, and collect better data.

I was excited to be invited to participate in a panel discussion alongside Arne Müller, Data Scientist, Digital Endpoints, Novartis; Carrie Northcott, Director, Digital Medicine & Translational Imaging, Pfizer; Sohini Chowdhury, Deputy CEO, Michael J. Fox Foundation for Parkinson’s Research. Christian Gossens, Global Head, Digital Biomarkers, Roche moderated a discussion focusing on the outlook of digital biomarkers in the post COVID-19 environment.

COVID-19 has given additional momentum to the digital transformation and the adoption of digital tools in the decentralization efforts of clinical trials. Watch the video to gain insight from industry leaders on the growth of clinical biomarker research.

Visit our Learning Center to watch our presentation that shares insight into our collaboration with ActiGraph in the development of a new biomarker.

Dudley Tabakin

Dudley Tabakin

Dudley Tabakin, MSc. is Chief Product Officer and co-founder of VivoSense and a fervent believer in “good data” over “big data" in the development of digital endpoints from wearable sensor technology.

Follow on:

Stay Connected